TG Therapeutics Reports Positive Phase 1 Data for BRIUMVI in Myasthenia Gravis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Results: TG Therapeutics' Phase 1 trial of BRIUMVI in myasthenia gravis patients revealed that 82% achieved the Minimal Clinically Important Difference in MG-ADL at Week 24, with a mean improvement of 4.6 points, indicating the drug's efficacy and potential market opportunity.
- Efficacy Maintenance Study: The company announced the initiation of a Phase 2 trial to evaluate the safety and efficacy of BRIUMVI in maintaining clinical response in myasthenia gravis patients who initially respond to the FcRn inhibitor efgartigimod, with an expected enrollment of about 120 patients to further validate the drug's long-term effects.
- Innovative Administration Method: The trial will initially utilize the approved intravenous dosing regimen of BRIUMVI, with subcutaneous administration to be incorporated later following the completion of pharmacokinetic bridging studies in multiple sclerosis, showcasing the company's flexibility and innovation in delivery methods.
- Market Performance: Currently, TG Therapeutics is trading at $42.51, up 3.81% on Nasdaq, reflecting positive market sentiment towards its clinical data and recognition of future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to fall
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 51.500
Low
15.00
Averages
43.50
High
60.00
Current: 51.500
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TG Therapeutics Reports Positive Results for Subcutaneous BRIUMVI
- Positive Clinical Results: TG Therapeutics reported that in a small study involving 11 patients with myasthenia gravis, most experienced significant improvements in daily symptoms after six months of treatment with the new subcutaneous BRIUMVI, indicating its efficacy and safety profile.
- Sales Forecast Increase: The company reported approximately $205 million in global revenue for Q1 2026 and raised its full-year sales forecast to about $925 million, reflecting strong market performance and growth potential for BRIUMVI.
- Investor Sentiment Shift: Despite a 2% increase in TG Therapeutics' stock price on Wednesday, retail sentiment shifted from 'extremely bullish' to 'bullish', indicating cautious optimism among investors regarding future catalysts and stock price movements.
- Analyst Ratings Optimistic: Among the nine analysts covering TGTX, seven rated it 'Buy' or higher, with a 12-month average price target of $48, demonstrating confidence in the company's future growth prospects.
See More
Trump's New Attacks on Iran Drive Oil Prices Up
- Oil Price Surge: Trump's new attacks on Iran have led to a rise in oil prices, heightening market tensions regarding the Middle East situation, which could destabilize future supply chains and impact the global economy.
- Futures Market Stability: While futures markets remained relatively unchanged, the increase in oil prices may raise investor concerns about inflation, potentially affecting stock market performance, particularly in energy-related stocks.
- Oracle Earnings Decline: Oracle's stock plummeted following disappointing earnings, reflecting market concerns about its future growth prospects, which may lead investors to reassess its position in the tech industry.
- SpaceX IPO Anticipation: The upcoming SpaceX IPO is generating significant market interest regarding its potential valuation and future growth, likely attracting a wave of investor attention and further fueling investment enthusiasm in the aerospace sector.
See More
Stock Market Volatility Driven by AI Fears and Trump's Iran Threats
- Market Volatility Drivers: The stock market experienced significant fluctuations on Tuesday, primarily due to heightened investor fears regarding artificial intelligence and threats from Trump concerning Iran, which led to a sharp decline in indices.
- Investor Sentiment Impact: The uncertainty surrounding future economic conditions has dampened investor sentiment, resulting in a rebound from lows but an overall weak trend, indicating a lack of confidence in economic recovery.
- Inflation Data Focus: The market is anticipating the upcoming Consumer Price Index (CPI) data release, with analysts widely expecting inflation to continue influencing monetary policy, potentially leading the Federal Reserve to adopt a more cautious stance.
- Future Outlook: Amid rapid advancements in AI technology, the market is filled with concerns regarding the prospects of related companies, prompting investors to closely monitor policy changes and global economic dynamics to adjust their investment strategies.
See More
TG Therapeutics Reports Positive Early Results for BRIUMVI in Myasthenia Gravis
- Clinical Trial Progress: TG Therapeutics announced encouraging early clinical trial results for its drug BRIUMVI in myasthenia gravis patients, with 82% of 11 patients showing significant improvement in daily activities within 24 weeks, demonstrating rapid efficacy and good tolerability.
- Indication Expansion: The company has initiated a larger mid-stage trial aimed at supporting future approval of BRIUMVI for myasthenia gravis, which, if successful, would broaden the drug's application beyond its current use in multiple sclerosis.
- Enhanced Treatment Convenience: The development of a subcutaneous formulation will allow patients to self-inject at home, avoiding the lengthy clinic infusions required for intravenous administration, which is expected to significantly improve patient adherence to treatment.
- Positive Market Reaction: TGTX shares rose 6% following the announcement, with analysts generally optimistic about the stock, as evidenced by a 12-month price target of $48, indicating a potential upside of about 11%, reflecting market confidence in the company's future prospects.
See More
TG Therapeutics Reports Positive Phase 1 Data for BRIUMVI in Myasthenia Gravis
- Clinical Trial Results: TG Therapeutics' Phase 1 trial of BRIUMVI in myasthenia gravis patients revealed that 82% achieved the Minimal Clinically Important Difference in MG-ADL at Week 24, with a mean improvement of 4.6 points, indicating the drug's efficacy and potential market opportunity.
- Efficacy Maintenance Study: The company announced the initiation of a Phase 2 trial to evaluate the safety and efficacy of BRIUMVI in maintaining clinical response in myasthenia gravis patients who initially respond to the FcRn inhibitor efgartigimod, with an expected enrollment of about 120 patients to further validate the drug's long-term effects.
- Innovative Administration Method: The trial will initially utilize the approved intravenous dosing regimen of BRIUMVI, with subcutaneous administration to be incorporated later following the completion of pharmacokinetic bridging studies in multiple sclerosis, showcasing the company's flexibility and innovation in delivery methods.
- Market Performance: Currently, TG Therapeutics is trading at $42.51, up 3.81% on Nasdaq, reflecting positive market sentiment towards its clinical data and recognition of future growth potential.
See More
TG Therapeutics Initiates Pivotal Mid-Stage Trial for Briumvi in Myasthenia Gravis
- Trial Initiation: TG Therapeutics announced the initiation of a pivotal mid-stage trial for Briumvi in myasthenia gravis (MG), expected to enroll approximately 120 patients, aiming to evaluate its efficacy in those previously responsive to efgartigimod, marking a significant milestone in expanding Briumvi's applications.
- Positive Early Data: The injectable formulation of Briumvi demonstrated drug exposures comparable to the intravenous form in 11 AChR-antibody-positive MG patients, consistently reducing myasthenia gravis outcome measures from baseline, indicating its therapeutic potential.
- Good Safety Profile: TG Therapeutics noted that the subcutaneous Briumvi was well tolerated, with a safety profile consistent with that of intravenous Briumvi, further enhancing its feasibility for clinical use.
- CEO's Optimistic Outlook: CEO Michael Weiss stated that these encouraging results support the continued development of Briumvi in MG and highlight the drug's potential utility beyond multiple sclerosis, reflecting the company's confidence in future market opportunities.
See More
TG Therapeutics Reports Positive Results for Subcutaneous BRIUMVI
- Positive Clinical Results: TG Therapeutics reported that in a small study involving 11 patients with myasthenia gravis, most experienced significant improvements in daily symptoms after six months of treatment with the new subcutaneous BRIUMVI, indicating its efficacy and safety profile.
- Sales Forecast Increase: The company reported approximately $205 million in global revenue for Q1 2026 and raised its full-year sales forecast to about $925 million, reflecting strong market performance and growth potential for BRIUMVI.
- Investor Sentiment Shift: Despite a 2% increase in TG Therapeutics' stock price on Wednesday, retail sentiment shifted from 'extremely bullish' to 'bullish', indicating cautious optimism among investors regarding future catalysts and stock price movements.
- Analyst Ratings Optimistic: Among the nine analysts covering TGTX, seven rated it 'Buy' or higher, with a 12-month average price target of $48, demonstrating confidence in the company's future growth prospects.
See More
Trump's New Attacks on Iran Drive Oil Prices Up
- Oil Price Surge: Trump's new attacks on Iran have led to a rise in oil prices, heightening market tensions regarding the Middle East situation, which could destabilize future supply chains and impact the global economy.
- Futures Market Stability: While futures markets remained relatively unchanged, the increase in oil prices may raise investor concerns about inflation, potentially affecting stock market performance, particularly in energy-related stocks.
- Oracle Earnings Decline: Oracle's stock plummeted following disappointing earnings, reflecting market concerns about its future growth prospects, which may lead investors to reassess its position in the tech industry.
- SpaceX IPO Anticipation: The upcoming SpaceX IPO is generating significant market interest regarding its potential valuation and future growth, likely attracting a wave of investor attention and further fueling investment enthusiasm in the aerospace sector.
See More
Stock Market Volatility Driven by AI Fears and Trump's Iran Threats
- Market Volatility Drivers: The stock market experienced significant fluctuations on Tuesday, primarily due to heightened investor fears regarding artificial intelligence and threats from Trump concerning Iran, which led to a sharp decline in indices.
- Investor Sentiment Impact: The uncertainty surrounding future economic conditions has dampened investor sentiment, resulting in a rebound from lows but an overall weak trend, indicating a lack of confidence in economic recovery.
- Inflation Data Focus: The market is anticipating the upcoming Consumer Price Index (CPI) data release, with analysts widely expecting inflation to continue influencing monetary policy, potentially leading the Federal Reserve to adopt a more cautious stance.
- Future Outlook: Amid rapid advancements in AI technology, the market is filled with concerns regarding the prospects of related companies, prompting investors to closely monitor policy changes and global economic dynamics to adjust their investment strategies.
See More
TG Therapeutics Reports Positive Early Results for BRIUMVI in Myasthenia Gravis
- Clinical Trial Progress: TG Therapeutics announced encouraging early clinical trial results for its drug BRIUMVI in myasthenia gravis patients, with 82% of 11 patients showing significant improvement in daily activities within 24 weeks, demonstrating rapid efficacy and good tolerability.
- Indication Expansion: The company has initiated a larger mid-stage trial aimed at supporting future approval of BRIUMVI for myasthenia gravis, which, if successful, would broaden the drug's application beyond its current use in multiple sclerosis.
- Enhanced Treatment Convenience: The development of a subcutaneous formulation will allow patients to self-inject at home, avoiding the lengthy clinic infusions required for intravenous administration, which is expected to significantly improve patient adherence to treatment.
- Positive Market Reaction: TGTX shares rose 6% following the announcement, with analysts generally optimistic about the stock, as evidenced by a 12-month price target of $48, indicating a potential upside of about 11%, reflecting market confidence in the company's future prospects.
See More
TG Therapeutics Reports Positive Phase 1 Data for BRIUMVI in Myasthenia Gravis
- Clinical Trial Results: TG Therapeutics' Phase 1 trial of BRIUMVI in myasthenia gravis patients revealed that 82% achieved the Minimal Clinically Important Difference in MG-ADL at Week 24, with a mean improvement of 4.6 points, indicating the drug's efficacy and potential market opportunity.
- Efficacy Maintenance Study: The company announced the initiation of a Phase 2 trial to evaluate the safety and efficacy of BRIUMVI in maintaining clinical response in myasthenia gravis patients who initially respond to the FcRn inhibitor efgartigimod, with an expected enrollment of about 120 patients to further validate the drug's long-term effects.
- Innovative Administration Method: The trial will initially utilize the approved intravenous dosing regimen of BRIUMVI, with subcutaneous administration to be incorporated later following the completion of pharmacokinetic bridging studies in multiple sclerosis, showcasing the company's flexibility and innovation in delivery methods.
- Market Performance: Currently, TG Therapeutics is trading at $42.51, up 3.81% on Nasdaq, reflecting positive market sentiment towards its clinical data and recognition of future growth potential.
See More
TG Therapeutics Initiates Pivotal Mid-Stage Trial for Briumvi in Myasthenia Gravis
- Trial Initiation: TG Therapeutics announced the initiation of a pivotal mid-stage trial for Briumvi in myasthenia gravis (MG), expected to enroll approximately 120 patients, aiming to evaluate its efficacy in those previously responsive to efgartigimod, marking a significant milestone in expanding Briumvi's applications.
- Positive Early Data: The injectable formulation of Briumvi demonstrated drug exposures comparable to the intravenous form in 11 AChR-antibody-positive MG patients, consistently reducing myasthenia gravis outcome measures from baseline, indicating its therapeutic potential.
- Good Safety Profile: TG Therapeutics noted that the subcutaneous Briumvi was well tolerated, with a safety profile consistent with that of intravenous Briumvi, further enhancing its feasibility for clinical use.
- CEO's Optimistic Outlook: CEO Michael Weiss stated that these encouraging results support the continued development of Briumvi in MG and highlight the drug's potential utility beyond multiple sclerosis, reflecting the company's confidence in future market opportunities.
See More
